Pitfalls of Physician-Directed Treatment of Helicobacter pylori: Results from Two Phase 3 Clinical Trials and Real-World Prescribing Data.

ABSTRACT:

Background

Helicobacter pylori (H. pylori) infects ~ 35% of Americans and can lead to serious sequelae if left untreated. Growing evidence indicates that clarithromycin-based therapies (CBT) are becoming increasingly ineffective for treating H. pylori infection. RHB-105 was approved by the US Food and Drug Administration in 2019 for the treatment of H. pylori infection in adults.

Aims

The primary aim of this study was to assess prescribing patterns and associated cure rates of physician-directed therapy for subjects with persistent H. pylori infection after participation in one of two Phase 3 clinical trials (ERADICATE Hp and ERADICATE Hp2).

Methods

We reviewed study reports to identify specific physician-directed regimens selected for subjects whose H. pylori infecti

SUBMITTER: Howden CW 

PROVIDER: S-EPMC9352601 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature